Related Experiment Video
Updated: May 15, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Impact of genetic targets on prostate cancer therapy
Hassan Sheikh1, Junaid Abdulghani, Suhail Ali
1Division of Hematology-Oncology, Penn State University, Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.
Abstract:
Given the global incidence of prostate cancer and its sociological impact, it remains a challenging disease to clinicians and researchers alike. In the last few years several new drugs have been added to the armamentarium of prostate cancer therapy and offers survival benefit to patients with prostate cancer. However, effective drugs are still needed that offer extended survival benefit and alter the natural history of the disease. Recent efforts have focused on better understanding the underlying biology and genetic heterogeneity of the disease and identified novel targets that can be utilized for drug development and therapeutics in the future. In this review we present an overview of the genetic landscape of prostate cancer, novel targets in the prostate cancer therapy and the results of key clinical trials of these novel drugs.
Insights
New prostate cancer therapies offer survival benefits, but more effective drugs are needed. This review covers the genetic landscape, novel therapeutic targets, and clinical trial results for advanced prostate cancer treatment.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Prostate cancer presents significant global health challenges.
- Recent advancements have introduced new therapies, yet improved survival and disease modification remain critical goals.
Purpose of the Study:
- To review the genetic landscape of prostate cancer.
- To highlight novel therapeutic targets for drug development.
- To summarize key clinical trial outcomes for emerging prostate cancer treatments.
Main Methods:
- Literature review of genetic heterogeneity in prostate cancer.
- Analysis of preclinical and clinical data for novel therapeutic targets.
- Synthesis of results from recent clinical trials evaluating new prostate cancer drugs.
Main Results:
- The genetic landscape of prostate cancer is complex and heterogeneous.
- Several novel targets have been identified, showing promise for future drug development.
- Key clinical trials demonstrate survival benefits with novel therapeutic agents.
Conclusions:
- Understanding prostate cancer's genetic basis is crucial for developing more effective therapies.
- Novel drug targets and ongoing clinical trials offer hope for improved patient outcomes and altered disease natural history.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...